Ramsey, A. V., Bischoff, A. J. & Francis, M. B. Enzyme activated gold nanoparticles for versatile site-selective bioconjugation. J. Am. Chem. Soc. 143, 7342–7350 (2021).
Chen, J. et al. Tocilizumab–conjugated polymer nanoparticles for NIR-II photoacoustic-imaging-guided therapy of rheumatoid arthritis. Adv. Mater. 32, 2003399 (2020).
Wang, X.-D., Rabe, K. S., Ahmed, I. & Niemeyer, C. M. Multifunctional silica nanoparticles for covalent immobilization of highly sensitive proteins. Adv. Mater. 27, 7945–7950 (2015).
Nel, A. E. et al. Understanding biophysicochemical interactions at the nano–bio interface. Nat. Mater. 8, 543–557 (2009).
Walkey, C. D. & Chan, W. C. W. Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. Chem. Soc. Rev. 41, 2780–2799 (2012).
Rabe, M., Verdes, D. & Seeger, S. Understanding protein adsorption phenomena at solid surfaces. Adv. Colloid Interface Sci. 162, 87–106 (2011).
Cao, Z.-T. et al. Protein binding affinity of polymeric nanoparticles as a direct indicator of their pharmacokinetics. ACS Nano 14, 3563–3575 (2020).
Estephan, Z. G., Jaber, J. A. & Schlenoff, J. B. Zwitterion-stabilized silica nanoparticles: toward nonstick nano. Langmuir 26, 16884–16889 (2010).
Debayle, M. et al. Zwitterionic polymer ligands: an ideal surface coating to totally suppress protein-nanoparticle corona formation? Biomaterials 219, 119357 (2019).
Vincent, M. P., Navidzadeh, J. O., Bobbala, S. & Scott, E. A. Leveraging self-assembled nanobiomaterials for improved cancer immunotherapy. Cancer Cell 40, 255–276 (2022).
Vincent, M. P., Bobbala, S., Karabin, N. B., Frey, M., Liu, Y., Navidzadeh, J. O., Stack, T. & Scott, E. A. Surface chemistry-mediated modulation of adsorbed albumin folding state specifies nanocarrier clearance by distinct macrophage subsets. Nat. Commun. 12, 648 (2021).
Vincent, M. P., Karabin, N. B., Allen, S. D., Bobbala, S., Frey, M. A., Yi, S., Yang, Y. & Scott, E. A. The combination of morphology and surface chemistry defines the immunological identity of nanocarriers in human blood. Adv. Ther. 4, 2100062 (2021).
Duan, S. et al. CD33 recruitment inhibits IgE-mediated anaphylaxis and desensitizes mast cells to allergen. J. Clin. Invest. 129, e125456 (2021).
Duan, S. et al. Nanoparticles displaying allergen and Siglec-8 ligands suppress IgE-FcεRI–mediated anaphylaxis and desensitize mast cells to subsequent antigen challenge. J. Immunol. 206, 2290–2300 (2021).
Albert, C. et al. Monobody adapter for functional antibody display on nanoparticles for adaptable targeted delivery applications. Nat. Commun. 13, 5998 (2022).
Tonigold, M. et al. Pre-adsorption of antibodies enables targeting of nanocarriers despite a biomolecular corona. Nat. Nanotechnol. 13, 862–869 (2018).
Schöttler, S. et al. Protein adsorption is required for stealth effect of poly(ethylene glycol)- and poly(phosphoester)-coated nanocarriers. Nat. Nanotechnol. 11, 372–377 (2016).
Kocbek, P., Obermajer, N., Cegnar, M., Kos, J. & Kristl, J. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J. Controlled Release 120, 18–26 (2007).
Du, F. et al. Homopolymer self-assembly of poly(propylene sulfone) hydrogels via dynamic noncovalent sulfone–sulfone bonding. Nat. Commun. 11, 4896 (2020).
Sun, H. et al. Origin of proteolytic stability of peptide-brush polymers as globular proteomimetics. ACS Cent. Sci. 7, 2063–2072 (2021).
Panganiban, B. et al. Random heteropolymers preserve protein function in foreign environments. Science 359, 1239–1243 (2018).
Qiao, B., Jiménez-Ángeles, F., Nguyen, T. D. & Olvera de la Cruz, M. Water follows polar and nonpolar protein surface domains. Proc. Natl Acad. Sci. USA 116, 19274–19281 (2019).
Kolkhir, P., Elieh-Ali-Komi, D., Metz, M., Siebenhaar, F. & Maurer, M. Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases. Nat. Rev. Immunol. 22, 294–308 (2022).
Valent, P. et al. Drug-induced mast cell eradication: a novel approach to treat mast cell activation disorders? J. Allergy Clin. Immunol. 149, 1866–1874 (2022).
Balbino, B. et al. The anti-IgE mAb omalizumab induces adverse reactions by engaging Fcγ receptors. J. Clin. Invest. 130, 1330–1335 (2020).
Galli, S. J., Gaudenzio, N. & Tsai, M. Mast cells in inflammation and disease: recent progress and ongoing concerns. Annu. Rev. Immunol. 38, 49–77 (2020).
Gotlib, J. et al. Proceedings from the inaugural American Initiative in Mast cell diseases (AIM) investigator conference. J. Allergy Clin. Immunol. 147, 2043–2052 (2021).
Robida, P. A. et al. Functional and phenotypic characterization of Siglec-6 on human mast cells. Cells 11, 1138 (2022).
Dispenza, M. C. et al. Bruton’s tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis. J. Clin. Investig. 130, 4759–4770 (2020).
Crocker, P. R., Paulson, J. C. & Varki, A. Siglecs and their roles in the immune system. Nat. Rev. Immunol. 7, 255–266 (2007).
Duan, S. et al. CD33 recruitment inhibits IgE-mediated anaphylaxis and desensitizes mast cells to allergen. J. Clin. Invest. 129, 1387–1401 (2019).
Macauley, M. S., Crocker, P. R. & Paulson, J. C. Siglec-mediated regulation of immune cell function in disease. Nat. Rev. Immunol. 14, 653–666 (2014).
Avril, T., Floyd, H., Lopez, F., Vivier, E. & Crocker, P. R. The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9, CD33-related siglecs expressed on human monocytes and NK cells1. J. Immunol. 173, 6841–6849 (2004).
Neuberger, M. S. et al. A hapten-specific chimaeric IgE antibody with human physiological effector function. Nature 314, 268–270 (1985).
Abraham, M. J. et al. GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1–2, 19–25 (2015).
Huang, J. et al. CHARMM36m: an improved force field for folded and intrinsically disordered proteins. Nat. Methods 14, 71–73 (2017).
Miyamoto, S. & Kollman, P. A. Settle: an analytical version of the SHAKE and RATTLE algorithm for rigid water models. J. Comput. Chem. 13, 952–962 (1992).
Humphrey, W., Dalke, A. & Schulten, K. VMD: visual molecular dynamics. J. Mol. Graph. 14, 33–38 (1996).
Caslin, H. L. et al. The use of human and mouse mast cell and basophil cultures to assess type 2 inflammation. Methods Mol. Biol. 1799, 81–92 (2018).
Bryce, P. J. et al. Humanized mouse model of mast cell-mediated passive cutaneous anaphylaxis and passive systemic anaphylaxis. J. Allergy Clin. Immunol. 138, 769–779 (2016).
Bao, C. et al. A mast cell-thermoregulatory neuron circuit axis regulates hypothermia in anaphylaxis. Sci. Immunol. 8, eadc9417 (2023).
Schanin, J. et al. Discovery of an agonistic Siglec-6 antibody that inhibits and reduces human mast cells. Commun. Biol. 5, 1226 (2022).
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.nature.com/articles/s41565-023-01584-z
